Bridged diazepan orexin receptor antagonists
View Patent ↗The present invention is directed to bridged diazepan compounds which are antagonists of orexin receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which orexin receptors are involved.
1. A compound of the formula I:
wherein:
X is selected from —SO 2 —, —(C═O)—, and —(C═S)—;
R 1 is selected from the group consisting of:
(1) phenyl, where the phenyl is substituted with R 1a , R 1b and R 1c ,
(2) naphthyl, where the naphthyl is substituted with R 1a , R 1b and R 1c , and
(3) heteroaryl, where the heteroaryl is substituted with R 1a , R 1b and R 1c ;
R 2 is heteroaryl, where the heteroaryl is substituted with R 2a , R 2b and R 2c ;
R 1a , R 1b , R 1c , R 2a , R 2b and R 2c are independently selected from the group consisting of:
(1) hydrogen,
(2) halogen,
(3) hydroxyl,
(4) —(C═O) m —O n —C 1-6 alkyl, where m is 0 or 1, n is 0 or 1 (wherein if m is 0 or n is 0, a bond is present) and where the alkyl is unsubstituted or substituted with one or more substituents selected from R 13 ,
(5) —(C═O) m —O n —C 3-6 cycloalkyl, where the cycloalkyl is unsubstituted or substituted with one or more substituents selected from R 13 ,
(6) —(C═O) m —C 2-4 alkenyl, where the alkenyl is unsubstituted or substituted with one or more substituents selected from R 13 ,
(7) —(C═O) m —C 2-4 alkynyl, where the alkynyl is unsubstituted or substituted with one or more substituents selected from R 13 ,
(8) —(C═O) m —O n -phenyl or —(C═O) m —O n -naphthyl, where the phenyl or naphthyl is unsubstituted or substituted with one or more substituents selected from R 13 ,
(9) —(C═O) m —O n -heterocycle, where the heterocycle is unsubstituted or substituted with one or more substituents selected from R 13 ,
(10) —(C═O) m —NR 10 R 11 , wherein R 10 and R 11 are independently selected from the group consisting of:
(a) hydrogen,
(b) C 1-6 alkyl, which is unsubstituted or substituted with one or more substituents selected from R 13 ,
(c) C 3-6 alkenyl, which is unsubstituted or substituted with one or more substituents selected from R 13 ,
(d) cycloalkyl, which is unsubstituted or substituted with one or more substituents selected from R 13 ,
(e) phenyl, which is unsubstituted or substituted with one or more substituents selected from R 13 , and
(f) heterocycle, which is unsubstituted or substituted with one or more substituents selected from R 13 ,
(11) —S(O) 2 —NR 10 R 11 ,
(12) —S(O) q —R 12 , where q is 0, 1 or 2 and where R 12 is selected from the definitions of R 10 and R 11 ,
(13) —CO 2 H,
(14) —CN, and
(15) —NO 2 ;
R 13 is selected from the group consisting of:
(1) halogen,
(2) hydroxyl,
(3) —(C═O) m —O n —C 1-6 alkyl, where the alkyl is unsubstituted or substituted with one or more substituents selected from R 14 ,
(4) —O n —(C 1-3 )perfluoroalkyl,
(5) —(C═O) m —O n —C 3-6 cycloalkyl, where the cycloalkyl is unsubstituted or substituted with one or more substituents selected from R 14 ,
(6) —(C═O) m —C 2-4 alkenyl, where the alkenyl is unsubstituted or substituted with one or more substituents selected from R 14 ,
(7) —(C═O) m —O n -phenyl or —(C═O) m —O n -naphthyl, where the phenyl or naphthyl is unsubstituted or substituted with one or more substituents selected from R 14 ,
(8) —(C═O) m —O n -heterocycle, where the heterocycle is unsubstituted or substituted with one or more substituents selected from R 14 ,
(9) —CO 2 H,
(10) —CN, and
(11) —NO 2 ;
R 14 is selected from the group consisting of:
(1) hydroxyl,
(2) halogen,
(3) C 1-6 alkyl,
(4) —C 3-6 cycloalkyl,
(5) —O—C 1-6 alkyl,
(6) —O(C═O)—C 1-6 alkyl,
(7) —NH—C 1-6 alkyl,
(8) phenyl,
(9) heterocycle,
(10) —CO 2 H, and
(11) —CN;
or a pharmaceutically acceptable salt thereof.
2. The compound of claim 1 of the formula Ib:
or a pharmaceutically acceptable salt thereof.
3. The compound of claim 1 wherein X is —SO 2 —.
4. The compound of claim 1 wherein R 1 is phenyl, which is unsubstituted or substituted with one or more of:
(1) halogen,
(2) hydroxyl,
(3) —O n —C 1-6 alkyl, where n is 0 or 1 (wherein if n is 0, a bond is present) and where the alkyl is unsubstituted or substituted with one or more substituents selected from R 13 ,
(4) —O n -phenyl, where the phenyl is unsubstituted or substituted with one or more substituents selected from R 13 ,
(5) -heterocycle, where the heterocycle is unsubstituted or substituted with one or more substituents selected from R 13 ,
(6) —NR 10 R 11 , wherein R 10 and R 11 are independently selected from the group consisting of:
(a) hydrogen,
(b) C 1-6 alkyl, which is unsubstituted or substituted with one or more substituents selected from R 13 ,
(7) —S(O) 2 —NR 10 R 11 ,
(8) —CO 2 H,
(9) —CN, and
(10) —NO 2 .
5. The compound of claim 4 wherein R 1 is selected from the group consisting of:
(1) phenyl,
(2) biphenyl,
(3) 2,6-dimethoxyphenyl,
(4) 2,4-dichlorophenyl,
(5) 2,6-dichlorophenyl,
(6) 2,3-difluorophenyl,
(7) 2,4-difluorophenyl,
(8) 2,6-difluorophenyl,
(9) 2-methoxy-4-methyl-phenyl,
(10) 3-methoxy-biphenyl,
(11) 3-methyl-biphenyl, and
(12) 5-methyl-2-triazolyl-phenyl.
6. The compound of claim 1 wherein R 2 is heteroaryl, which is unsubstituted or substituted with one or more of:
(1) halogen,
(2) hydroxyl,
(3) —O n —C 1-6 alkyl, where n is 0 or 1 (wherein if n is 0, a bond is present) and where the alkyl is unsubstituted or substituted with one or more substituents selected from R 13 ,
(4) —O n -phenyl, where the phenyl is unsubstituted or substituted with one or more substituents selected from R 13 ,
(5) -heterocycle, where the heterocycle is unsubstituted or substituted with one or more substituents selected from R 13 ,
(6) —NR 10 R 11 , wherein R 10 and R 11 are independently selected from the group consisting of:
(a) hydrogen,
(b) C 1-6 alkyl, which is unsubstituted or substituted with one or more substituents selected from R 13 ,
(7) —S(O) 2 —NR 10 R 11 ,
(8) —CO 2 H,
(9) —CN, and
(10) —NO 2 .
7. The compound of claim 5 wherein R 2 is selected from the group consisting of:
(1) benzimidazolyl,
(2) benzothiazolyl,
(3) benzoxazolyl,
(4) quinazolinyl,
(5) quinolinyl, and
(6) thiadiazolyl,
which is unsubstituted or substituted with halogen, hydroxyl, C 1-6 alkyl, —O—C 1-6 alkyl or phenyl.
8. A compound which is selected from the group consisting of:
2-{3-[5-Methyl-2-(2H-1,2,3-triazol-2-yl)benzoyl]-3,6-diazabicyclo[3.2.1]oct-6-yl}quinazoline;
(R,R)-2-{3-[5-Methyl-2-(2H-1,2,3-triazol-2-yl)benzoyl]-3,6-diazabicyclo[3.2.1]oct-6-yl}quinazoline;
(S,S)-2-{3-[5-Methyl-2-(2H-1,2,3-triazol-2-yl)benzoyl]-3,6-diazabicyclo[3.2.1]oct-6-yl}quinazoline;
6-Chloro-2-{3-[5-methyl-2-(2H-1,2,3-triazol-2-yl)benzoyl]-3,6-diazabicyclo[3.2.1]oct-6-yl}[1,3]oxazolo[5,4-b]pyridine;
6-Fluoro-2-{3-[5-methyl-2-(2H-1,2,3-triazol-2-yl)benzoyl]-3,6-diazabicyclo[3.2.1]oct-6-yl}quinazoline;
6-Fluoro-2-{3-[5-methyl-2-(2H-1,2,3-triazol-2-yl)benzoyl]-3,6-diazabicyclo[3.2.1]oct-6-yl}[1,3]oxazolo[5,4-b]pyridine;
2-[3-(2,6-Dimethoxybenzoyl)-3,6-diazabicyclo[3.2.1]oct-6-yl]quinazoline;
2-{3-[(2-Methyl-5-phenyl-1,3-thiazol-4-yl)carbonyl]-3,6-diazabicyclo[3.2.1]oct-6-yl}quinazoline;
2-[3-(Biphenyl-2-ylcarbonyl)-3,6-diazabicyclo[3.2.1]oct-6-yl]quinazoline;
2-{3-[2-Fluoro-6-(2H-1,2,3-triazol-2-yl)benzoyl]-3,6-diazabicyclo[3.2.1]oct-6-yl}quinazoline;
2-{3-[5-Fluoro-2-(2H-1,2,3-triazol-2-yl)benzoyl]-3,6-diazabicyclo[3.2.1]oct-6-yl}quinazoline;
2-{3-[5-Bromo-2-(2H-1,2,3-triazol-2-yl)benzoyl]-3,6-diazabicyclo[3.2.1]oct-6-yl}quinazoline;
2-{3-[2-(2H-1,2,3-Triazol-2-yl)benzoyl]-3,6-diazabicyclo[3.2.1]oct-6-yl}quinazoline;
3-[5-Methyl-2-(2H-1,2,3-triazol-2-yl)benzoyl]-6-(6-phenylpyrazin-2-yl)-3,6-diazabicyclo[3.2.1]octane;
3-[5-Methyl-2-(2H-1,2,3-triazol-2-yl)benzoyl]-6-(2-phenylpyrimidin-4-yl)-3,6-diazabicyclo[3.2.1]octane;
6-Chloro-2-{3-[5-methyl-2-(2H-1,2,3-triazol-2-yl)benzoyl]-3,6-diazabicyclo[3.2.1]oct-6-yl}-1,3-benzothiazole;
5-Chloro-2-{3-[5-methyl-2-(2H-1,2,3-triazol-2-yl)benzoyl]-3,6-diazabicyclo[3.2.1]oct-6-yl}-1,3-benzoxazole;
3-[5-Methyl-2-(2H-1,2,3-triazol-2-yl)benzoyl]-6-(4-phenylpyrimidin-2-yl)-3,6-diazabicyclo[3.2.1]octane;
6,7-Difluoro-2-{3-[5-methyl-2-(2H-1,2,3-triazol-2-yl)benzoyl]-3,6-diazabicyclo[3.2.1]oct-6-yl}quinoxaline;
2-{3-[5-Methyl-2-(2H-1,2,3-triazol-2-yl)benzoyl]-3,6-diazabicyclo[3.2.1]oct-6-yl}quinoxaline;
or a pharmaceutically acceptable salt thereof.
9. A pharmaceutical composition which comprises an inert carrier and a compound of claim 1 or a pharmaceutically acceptable salt thereof.
10. A method for enhancing the quality of sleep in a mammalian patient in need thereof which comprises administering to the patient a therapeutically effective amount of the compound of claim 1 or a pharmaceutically acceptable salt thereof.
11. A method for treating insomnia in a mammalian patient in need thereof which comprises administering to the patient a therapeutically effective amount of the compound of claim 1 or a pharmaceutically acceptable salt thereof.
12. A method for treating or controlling obesity in a mammalian patient in need thereof which comprises administering to the patient a therapeutically effective amount of the compound of claim 1 or a pharmaceutically acceptable salt thereof.